- Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
- Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
- Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
- Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
- Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
- Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
- Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
- Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024
- Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.78 |
---|---|
High | 1.99 |
Low | 1.41 |
Bid | 1.51 |
Offer | 1.52 |
Previous close | 2.30 |
Average volume | 434.72k |
---|---|
Shares outstanding | 1.32m |
Free float | 1.22m |
P/E (TTM) | -- |
Market cap | 3.03m USD |
EPS (TTM) | -26.72 USD |
Data delayed at least 15 minutes, as of Apr 25 2024 21:00 BST.
More ▼